Monoclonal Antibody-based Targeted Therapy in Breast Cancer: Current Status and Future Directions

Overview

Journal Drugs

Specialty Pharmacology

Date 2006 Sep 8

PMID 16956305

Citations 18

Authors

Chantal Bernard-Marty

Fabienne Lebrun

Ahmad Awada

Martine J Piccart

Affiliations

Soon will be listed here.

Abstract

The recent development of monoclonal antibodies targeting growth factor receptors in cancer treatment represents a milestone for both researchers and physicians. Advances in the understanding of key molecular pathways for tumour growth and survival have facilitated the development of these targeted therapies, in particular in breast cancer. This review focuses on the three most important recombinant humanised monoclonal antibodies that have shown activity in women with breast cancer: trastuzumab, pertuzumab and bevacizumab. Trastuzumab, an anti-erbB2 (human epidermal growth factor receptor) monoclonal antibody, is currently routinely used in both the metastatic and adjuvant settings for patients with erbB2-positive tumours. Pertuzumab, a monoclonal antibody binding to a different epitope on erbB2 than trastuzumab, is under early clinical evaluation. This drug has been developed for breast cancer patients, whether overexpressing erbB2 or not. Bevacizumab, a monoclonal antibody directed against vascular endothelial growth factor-A, is being evaluated in the metastatic setting for its antiangiogenic properties, and is showing promising results.

Citing Articles

Breast cancer immunotherapy: a comprehensive review.

Keshavarz S, Wall J, Keshavarz S, Vojoudi E, Jafari-Shakib R Clin Exp Med. 2023; 23(8):4431-4447.

PMID: 37658246 DOI: 10.1007/s10238-023-01177-z.

Monoclonal Antibodies and Antibody-drug Conjugates as Emerging Therapeutics for Breast Cancer Treatment.

Saini S, Gulati N, Awasthi R, Arora V, Singh S, Kumar S Curr Drug Deliv. 2023; 21(7):993-1009.

PMID: 37519200 DOI: 10.2174/1567201820666230731094258.

Nanomedicine Technologies for Diagnosis and Treatment of Breast Cancer.

Kitsios K, Sharifi S, Mahmoudi M ACS Pharmacol Transl Sci. 2023; 6(5):671-682.

PMID: 37200812 PMC: 10186357. DOI: 10.1021/acsptsci.3c00044.

Role of Immune Cells and Receptors in Cancer Treatment: An Immunotherapeutic Approach.

Mukherjee A, Wanjari U, Namachivayam A, Murali R, Prabakaran D, Ganesan R Vaccines (Basel). 2022; 10(9).

PMID: 36146572 PMC: 9502517. DOI: 10.3390/vaccines10091493.

Engineered bispecific antibodies targeting the interleukin-6 and -8 receptors potently inhibit cancer cell migration and tumor metastasis.

Yang H, Karl M, Wang W, Starich B, Tan H, Kiemen A Mol Ther. 2022; 30(11):3430-3449.

PMID: 35841152 PMC: 9637575. DOI: 10.1016/j.ymthe.2022.07.008.

References

Bianco R, Shin I, Ritter C, Yakes F, Basso A, Rosen N . Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene. 2003; 22(18):2812-22. DOI: 10.1038/sj.onc.1206388. View

Venturini M, Bighin C, Monfardini S, Cappuzzo F, Olmeo N, Durando A . Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2005; 95(1):45-53. DOI: 10.1007/s10549-005-9030-x. View

Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz C, Dantis L . Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol. 1999; 26(4 Suppl 12):78-83. View

Sledge Jr G . Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects. Semin Oncol. 2002; 29(3 Suppl 11):104-10. DOI: 10.1053/sonc.2002.34062. View

Miller K, Chap L, Holmes F, Cobleigh M, Marcom P, Fehrenbacher L . Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005; 23(4):792-9. DOI: 10.1200/JCO.2005.05.098. View

Baselga J, Norton L, Albanell J, Kim Y, Mendelsohn J . Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998; 58(13):2825-31. View

Motoyama A, Hynes N, Lane H . The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res. 2002; 62(11):3151-8. View

Nahta R, Esteva F . HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res. 2003; 9(14):5078-84. View

Leyland-Jones B, Gelmon K, Ayoub J, Arnold A, Verma S, Dias R . Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol. 2003; 21(21):3965-71. DOI: 10.1200/JCO.2003.12.109. View

10.

Neshat M, Mellinghoff I, Tran C, Stiles B, Thomas G, Petersen R . Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A. 2001; 98(18):10314-9. PMC: 56958. DOI: 10.1073/pnas.171076798. View

11.

Friess T, Scheuer W, Hasmann M . Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Clin Cancer Res. 2005; 11(14):5300-9. DOI: 10.1158/1078-0432.CCR-04-2642. View

12.

Tedesco K, Thor A, Johnson D, Shyr Y, Blum K, Goldstein L . Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol. 2004; 22(6):1071-7. DOI: 10.1200/JCO.2004.10.046. View

13.

Perez E, Suman V, Rowland K, Ingle J, Salim M, Loprinzi C . Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005; 6(5):425-32. DOI: 10.3816/CBC.2005.n.047. View

14.

Piccart-Gebhart M, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I . Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1659-72. DOI: 10.1056/NEJMoa052306. View

15.

Kubo M, Morisaki T, Kuroki H, Tasaki A, Yamanaka N, Matsumoto K . Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer. Anticancer Res. 2003; 23(6a):4443-9. View

16.

Linderholm B, Andersson J, Lindh B, Beckman L, Erlanson M, Edin K . Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment. Eur J Cancer. 2003; 40(1):33-42. DOI: 10.1016/s0959-8049(03)00673-7. View

17.

Ellis M, Coop A, Singh B, Mauriac L, Janicke F, Miller W . Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001; 19(18):3808-16. DOI: 10.1200/JCO.2001.19.18.3808. View

18.

Willett C, Boucher Y, Tomaso E, Duda D, Munn L, Tong R . Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004; 10(2):145-7. PMC: 2693485. DOI: 10.1038/nm988. View

19.

Seidman A, Hudis C, Pierri M, Shak S, Paton V, Ashby M . Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002; 20(5):1215-21. DOI: 10.1200/JCO.2002.20.5.1215. View

20.

Vogel C, Cobleigh M, Tripathy D, Gutheil J, Harris L, Fehrenbacher L . Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20(3):719-26. DOI: 10.1200/JCO.2002.20.3.719. View